Leah Kuntz

The FDA has granted Fast Track designation to posdinemab, a phosphorylated tau-directed monoclonal antibody being investigated for the treatment of patients with early Alzheimer disease.

Check out the positive topline results from a phase 2 dose finding trial evaluating N-methyl amisulpride (LB-102) in adult patients with acute schizophrenia.

Do you want to be featured in a future Special Report? Check out our January theme!

Navacaprant for the treatment of major depressive disorder has failed in the phase 3 KOASTAL-1 trial.

Let's review the Special Reports of 2024!

Need CME credit? We've got a present for you!

A recent longitudinal, retrospective study aimed to examine antipsychotic prescribing and rehospitalization rates in a forensic psychiatric sample.

New positive topline results from an open-label phase 2a study of IV psilocin benzoate in patients with major depressive disorder showed that the treatment delivers rapid, lasting antidepressant effects for up to 3 months following a single dose.

Intra-Cellular Therapies has submitted an sNDA for lumateperone for the treatment of major depressive disorder in adults as adjunctive therapy to antidepressants.

Do you want to be featured in our online series? Check out our December theme!

In the phase 3 ENCORE trial, AXS-12 reduced the frequency of cataplexy attacks as compared with placebo at week 3 of the double-blind period.

According to new data, NeuroStar Advanced TMS helped nearly 60% of adolescents with major depressive disorder.

Check out new results of a pharmacokinetics study of AD04, an investigational therapeutic agent for the treatment of alcohol use disorder in patients with heavy drinking.

The FDA has granted clearance to the Horizon Inspire transcranial magnetic stimulation system to treat major depressive disorder, obsessive-compulsive disorder, and anxious depression.

Emraclidine once-daily, oral monotherapy treatment for adults with schizophrenia experiencing acute psychotic symptoms, failed to meet the primary endpoints in the 2 phase 2 EMPOWER trials.

New positive results demonstrate the efficacy and safety of lumateperone (Caplyta) 42 mg for the prevention of relapse in adult patients with schizophrenia.

A new collaboration to address sleep disturbances associated with cognitive impairment, an unmet need.

How can we lessen fatal interactions between individuals with mental illness and police? The best possible avenue is partnership and cooperation between mental health clinicians and law enforcement.

Do you want to be featured in our online series and potentially in print? Check out our November theme!

Posters from the conference confirm the durability of long-term treatment with xanomeline/trospium (Cobenfy).

Need CME credit? Check out these articles.

The CDC just released new data that highlight issues around adult ADHD prevalence, diagnosis, and treatment.

The FDA has granted Fast Track designation to liafensine for the treatment of patients with treatment-resistant depression.

Do you want to be featured in our online series and potentially in print for an upcoming Special Report? Check out our October theme!

Multiple sites are now enrolling participants in a phase 2 clinical trial to evaluate SPG302, the first synaptic regenerative therapy for schizophrenia.

New data informs clinicians of how best to switch patients from a once-monthly subcutaneous injection of RBP-7000 (Perseris) to risperidone (Uzedy), an extended-release injectable suspension of risperidone for subcutaneous use every 1 or 2 months for the treatment of schizophrenia in adults.

Check out new positive efficacy, safety, and tolerability results from the phase 3 SOLARIS trial evaluating TEV-‘749 in adult patients diagnosed with schizophrenia.

A new analysis from a 3-year open-label extension study revealed that treatment with deutetrabenazine was associated with long term improvement of symptoms of tardive dyskinesia.

Enter your email to check out this complicated case!

A new study of adult emergency department admissions found that individuals taking high doses of amphetamine—like Adderall—have a 5-fold increased risk for developing psychosis or mania.